Alzamend Neuro is trading 7.05% down in pre-market at $1.45 after a filing disclosed an offering of up to 98,388,305 shares by selling stockholders.
- The potential share supply appears to be the clearest company-specific overhang for August 24, 2026; the filing was reported on August 21.
- No newer company announcement was identified.
- Nasdaq futures are down 0.58%, but the offering remains the more direct explanation.